Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11489791 | 0.89 | MAOB (0.47) | MAOBADAM17SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11077137 | 0.85 | MAOB (0.46) | MAOBSLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL11079999 | 0.85 | MAOB (0.46) | MAOBSLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL10651717 | 0.85 | MAOB (0.46) | MAOBSLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL8572147 | 0.79 | MAOB (0.49) | MAOBSLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL17792929 | 0.79 | ALDH1A1 (0.47) | ADAM17SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL6628664 | 0.76 | CHRM1 (0.56) | MAOBSLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL12459423 | 0.75 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL2475580 | 0.75 | SLC6A2 (0.50) | MAOBSLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL3422142 | 0.75 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201580-A1 | PYRROLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-08-18 | — | — | US | disclosed |
| WO-2011095535-A2 | PYRROLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201580-A1 | PYRROLIDINE DERIVATIVES | IL5, TSLP, NR3C1 | MAOB 2121/4885ADAM17 4367/4885SLC6A2 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.